Interview: KaNDy Menopause Therapy Hits Sweet Spot
NT-814 Set For Phase III Trials
Executive Summary
Prospective partners will be impressed by data which shows that the UK company's once-daily oral treatment reduces hot flashes and night sweats and has also shown very rapid improvements in mood and sleep.
You may also be interested in...
Bayer Backs Hot Flashes Drug For Blockbuster Status
The menopause drug elinzanetant, which has just gone into Phase III, has joined Kerendia, Verquvo and Nubeqa as a candidate that Bayer believes has a peak sales potential of more than €1bn.
GSK Spin-Off Launches KaNDy To Tackle Key Symptoms Of Menopause
NeRRe Therapeutics has set up a new entity around a drug which it believes could be an effective alternative to hormone replacement therapy for hot flashes that may rapidly reduce debilitating sleep disturbance.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.